From the Journals

Radiation offers no survival benefit in early lung cancer with positive margins


 

FROM THE JOURNAL OF SURGICAL RESEARCH


Five-year survival was 34.5% for patients with reportedly positive margins, versus 57.2% for patients without positive margins, according to results of an unadjusted analysis.

To evaluate the effects of radiotherapy specifically for treatment of positive margins, the investigators excluded patients who had upstaged disease or who had received palliative radiotherapy. Out of the remaining 1,579 patients, 579 (38.2%) received radiation therapy, according to the report.

In that group, there was no significant difference in likelihood of death associated with radiation treatment (hazard ratio, 1.10, 95% confidence interval, 0.90-1.35).

“Despite the importance of these findings, there is still potential for substantial bias in this retrospective study, and therefore prospective investigation is necessary in order to validate our results,” Dr. Gulack and his colleagues concluded.

Study coauthor Thomas A. D’Amico, MD, reported serving as a consultant for Scanlan, and the rest of the authors had no disclosures.

SOURCE: Gulack et al. J Surg Res 2018 March doi: 10.1016/j.jss.2017.10.025.

Pages

Recommended Reading

New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Analysis of Twitter lung cancer content reveals opportunity for clinicians
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
States judged on smoking cessation services
MDedge Hematology and Oncology
Preoperative exercise lowers postoperative lung resection complications
MDedge Hematology and Oncology
Two biomarkers predict immunotherapy response for NSCLC
MDedge Hematology and Oncology
Radiation exposure in MICU may exceed recommended limit
MDedge Hematology and Oncology
The T-cell repertoire in NSCLC: Therapeutic implications
MDedge Hematology and Oncology
Imfinzi approved for stage III unresectable NSCLC
MDedge Hematology and Oncology
Hospitalizations for fracture in patients with metastatic disease: primary source lesions in the United States
MDedge Hematology and Oncology